Compare Moderna, Inc. (MRNA) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Snap Inc — how do they compare? Moderna, Inc. trades at $196.07 (market cap $78.65B), while Snap Inc trades at $5.9 (market cap $9.83B). The key difference: Moderna, Inc. is far larger — about 8× Snap Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Snap Inc for 68 Days on average.
| MRNA | SNAP | |
|---|---|---|
Market Cap | $78.65B | $9.83B |
Volume | 37,373,437 | 28,532,342 |
Sector | Health | Media |
52-Week High | $203.46 | $9.09 |
52-Week Low | $22.36 | $3.93 |
Typical Hold Time | 59 Days | 68 Days |
Enterprise Value | $74.80B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Snap Inc. (SNAP) trades at $5.81, up 0.17% with a bullish technical signal. The company shows improving fundamentals with revenue growth to $5.93B in 2025 and narrowing losses (-$460M vs -$1.4B in 2022). Recent news highlights AI integration in SPECS glasses with NVIDIA and Salesforce partnerships. Analyst consensus is mixed with 38% buy ratings and $7.78 price target, representing 34% upside potential.
Snap presents a turnaround story with improving financials but remains unprofitable. The stock offers potential upside from AI initiatives and revenue growth, balanced by competitive pressures and regulatory risks. Current valuation at 1.55 P/S appears reasonable for the growth trajectory, though profitability remains the key hurdle for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
